FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2799576879> ?p ?o ?g. }

• W2799576879 endingPage "24560" @default.
• W2799576879 startingPage "24548" @default.
• W2799576879 abstract "// Feng Li 1, 2, 3, 4 , Zhichao Liao 1, 2, 3, 4 , Chao Zhang 1, 2, 3, 4 , Jun Zhao 1, 2, 3, 4 , Ruwei Xing 1, 2, 3, 4 , Sheng Teng 1, 2, 3, 4 , Jin Zhang 1, 2, 3, 4 , Yun Yang 1, 2, 3, 4 and Jilong Yang 1, 2, 3, 4 1 Department of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, People’s Republic of China 2 National Clinical Research Center of Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, People’s Republic of China 3 Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, People’s Republic of China 4 Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, People’s Republic of China Correspondence to: Jilong Yang, email: yangjilong@tjmuch.com Keywords: apatinib; sarcoma; targeted therapy; efficacy; safety Received: December 13, 2017     Accepted: February 25, 2018     Published: May 11, 2018 ABSTRACT Sarcomas are a group of malignant tumors originating from mesenchymal tissue with a variety of cell subtypes. Despite several major treatment breakthroughs, standard treatment using surgery, radiation, and chemotherapy has failed to improve overall survival. Therefore, there is an urgent need to explore new strategies and innovative therapies to further improve the survival rates of patients with sarcomas. Pathological angiogenesis has an important role in the growth and metastasis of tumors. Vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptors (VEGFRs) play a central role in tumor angiogenesis and represent potential targets for anticancer therapy. As a novel targeted therapy, especially with regard to angiogenesis, apatinib is a new type of small molecule tyrosine kinase inhibitor that selectively targets VEGFR-2 and has shown encouraging anticancer activity in a wide range of malignancies, including gastric cancer, non-small cell lung cancer, breast cancer, hepatocellular carcinoma, and sarcomas. In this review, we summarize the preclinical and clinical data for apatinib, focusing primarily on its use in the treatment of sarcomas." @default.
• W2799576879 created "2018-05-17" @default.
• W2799576879 creator A5005368388 @default.
• W2799576879 creator A5030638246 @default.
• W2799576879 creator A5031831728 @default.
• W2799576879 creator A5032256529 @default.
• W2799576879 creator A5036229509 @default.
• W2799576879 creator A5049646905 @default.
• W2799576879 creator A5055174519 @default.
• W2799576879 creator A5066026439 @default.
• W2799576879 creator A5081844561 @default.
• W2799576879 date "2018-05-11" @default.
• W2799576879 modified "2023-09-25" @default.
• W2799576879 title "Apatinib as targeted therapy for sarcoma" @default.
• W2799576879 cites W1566324554 @default.
• W2799576879 cites W1725090888 @default.
• W2799576879 cites W1816099873 @default.
• W2799576879 cites W1868766650 @default.
• W2799576879 cites W1968532316 @default.
• W2799576879 cites W1969148752 @default.
• W2799576879 cites W1981186476 @default.
• W2799576879 cites W1999464994 @default.
• W2799576879 cites W2001658518 @default.
• W2799576879 cites W2018826865 @default.
• W2799576879 cites W2038533540 @default.
• W2799576879 cites W2046516822 @default.
• W2799576879 cites W2056163905 @default.
• W2799576879 cites W2065550467 @default.
• W2799576879 cites W2068923084 @default.
• W2799576879 cites W2105968397 @default.
• W2799576879 cites W2107230638 @default.
• W2799576879 cites W2112657305 @default.
• W2799576879 cites W2113935263 @default.
• W2799576879 cites W2118471037 @default.
• W2799576879 cites W2127459809 @default.
• W2799576879 cites W2144530818 @default.
• W2799576879 cites W2145092426 @default.
• W2799576879 cites W2147132125 @default.
• W2799576879 cites W2160060092 @default.
• W2799576879 cites W2164470179 @default.
• W2799576879 cites W2166271687 @default.
• W2799576879 cites W2166573361 @default.
• W2799576879 cites W2170583701 @default.
• W2799576879 cites W2257331168 @default.
• W2799576879 cites W2276228008 @default.
• W2799576879 cites W2283064216 @default.
• W2799576879 cites W2488257907 @default.
• W2799576879 cites W2511789742 @default.
• W2799576879 cites W2566159668 @default.
• W2799576879 cites W2570618306 @default.
• W2799576879 cites W2594982122 @default.
• W2799576879 cites W2606756302 @default.
• W2799576879 cites W2617206715 @default.
• W2799576879 cites W2707326909 @default.
• W2799576879 cites W2747013364 @default.
• W2799576879 cites W2747989445 @default.
• W2799576879 cites W2751140959 @default.
• W2799576879 cites W2773643761 @default.
• W2799576879 cites W2775931026 @default.
• W2799576879 cites W278389767 @default.
• W2799576879 cites W2890721143 @default.
• W2799576879 cites W2068734996 @default.
• W2799576879 doi "https://doi.org/10.18632/oncotarget.24647" @default.
• W2799576879 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5966248" @default.
• W2799576879 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29849960" @default.
• W2799576879 hasPublicationYear "2018" @default.
• W2799576879 type Work @default.
• W2799576879 sameAs 2799576879 @default.
• W2799576879 citedByCount "14" @default.
• W2799576879 countsByYear W27995768792019 @default.
• W2799576879 countsByYear W27995768792020 @default.
• W2799576879 countsByYear W27995768792021 @default.
• W2799576879 countsByYear W27995768792022 @default.
• W2799576879 crossrefType "journal-article" @default.
• W2799576879 hasAuthorship W2799576879A5005368388 @default.
• W2799576879 hasAuthorship W2799576879A5030638246 @default.
• W2799576879 hasAuthorship W2799576879A5031831728 @default.
• W2799576879 hasAuthorship W2799576879A5032256529 @default.
• W2799576879 hasAuthorship W2799576879A5036229509 @default.
• W2799576879 hasAuthorship W2799576879A5049646905 @default.
• W2799576879 hasAuthorship W2799576879A5055174519 @default.
• W2799576879 hasAuthorship W2799576879A5066026439 @default.
• W2799576879 hasAuthorship W2799576879A5081844561 @default.
• W2799576879 hasBestOaLocation W27995768791 @default.
• W2799576879 hasConcept C121608353 @default.
• W2799576879 hasConcept C126322002 @default.
• W2799576879 hasConcept C143998085 @default.
• W2799576879 hasConcept C2779013556 @default.
• W2799576879 hasConcept C2780668389 @default.
• W2799576879 hasConcept C2781230642 @default.
• W2799576879 hasConcept C71924100 @default.
• W2799576879 hasConceptScore W2799576879C121608353 @default.
• W2799576879 hasConceptScore W2799576879C126322002 @default.
• W2799576879 hasConceptScore W2799576879C143998085 @default.
• W2799576879 hasConceptScore W2799576879C2779013556 @default.
• W2799576879 hasConceptScore W2799576879C2780668389 @default.
• W2799576879 hasConceptScore W2799576879C2781230642 @default.
• W2799576879 hasConceptScore W2799576879C71924100 @default.

• next